TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.110
+0.132 (13.44%)
Nov 26, 2025, 4:00 PM EST - Market closed

TScan Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
6317227937107-
Upgrade
Market Cap Growth
-79.43%-38.39%647.03%-65.09%--
Upgrade
Enterprise Value
-26-9150-66-69-
Upgrade
Last Close Price
1.113.045.831.554.50-
Upgrade
PS Ratio
7.4861.0013.252.7610.54-
Upgrade
PB Ratio
0.440.711.850.380.67-
Upgrade
P/TBV Ratio
0.440.711.850.380.67-
Upgrade
EV/Sales Ratio
--7.14---
Upgrade
Debt / Equity Ratio
0.660.400.610.870.040.43
Upgrade
Asset Turnover
0.030.010.090.070.090.02
Upgrade
Quick Ratio
6.328.076.446.947.561.99
Upgrade
Current Ratio
6.448.146.517.177.762.09
Upgrade
Return on Equity (ROE)
-76.44%-65.08%-71.29%-50.90%-54.64%-87.44%
Upgrade
Return on Assets (ROA)
-30.45%-26.20%-24.79%-21.51%-25.56%-33.08%
Upgrade
Return on Capital (ROIC)
-33.24%-28.97%-27.25%-23.65%-31.75%-45.49%
Upgrade
Return on Capital Employed (ROCE)
-63.80%-40.20%-38.60%-36.70%-29.20%-81.20%
Upgrade
Earnings Yield
-226.38%-74.22%-32.00%-177.43%-45.48%-
Upgrade
FCF Yield
-215.67%-66.74%-23.14%-189.50%-54.82%-
Upgrade
Buyback Yield / Dilution
-6.36%-18.32%-98.89%-106.20%-1173.20%-137.86%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q